The Impact of Step Therapy on Individuals with Psoriatic Disease in the USA: Patient and Provider Perspectives
Open Access
- 3 May 2025
- journal article
- editorial
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (7) , 1599-1606
Abstract
The management of psoriatic disease has been revolutionized by biologic medications in recent years. Despite their efficacy and safety, patients are often required by insurance plans in the USA or national formulary guidelines in other countries to try and fail other treatments first, which is a strategy called step therapy. Originally designed to contain costs of specialty drugs, step therapy has a number of negative impacts on patients and providers, both personally and clinically. This article is coauthored by a patient with psoriasis and psoriatic arthritis who navigated step therapy. She describes her early experiences with psoriasis and achieving disease control with biologic medication, only to later be diagnosed with psoriatic arthritis and need to revise this treatment plan. She then explains how insurance denials and step therapy impact her life physically, emotionally, socially, and medically. This case is then discussed from the perspective of a dermatologist specializing in inflammatory skin disease. We highlight the psychosocial burden of psoriatic disease, as well as the burden of step therapy and its impacts on patients, providers, and the entire medical system.Keywords
This publication has 27 references indexed in Scilit:
- Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients with Rheumatoid or Psoriatic ArthritisPharmacoEconomics - Open, 2019
- Psoriatic Arthritis: What is Happening at the Joint?Rheumatology and Therapy, 2019
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologicsJournal of the American Academy of Dermatology, 2019
- Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transitionNature Reviews Rheumatology, 2019
- 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic ArthritisArthritis & Rheumatology, 2018
- Transplant recipients are vulnerable to coverage denial under Medicare Part DAmerican Journal of Transplantation, 2018
- Psoriasis and suicidality: A systematic review and meta-analysisJournal of the American Academy of Dermatology, 2017
- Impact of a Pregabalin Step Therapy Policy Among Medicare Advantage BeneficiariesPain Practice, 2013
- Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011PLOS ONE, 2012
- Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medicationsClinical Therapeutics, 2008